STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma.

@article{Ito2007STAT3PP,
  title={STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma.},
  author={N. Ito and M. Eto and E. Nakamura and A. Takahashi and T. Tsukamoto and H. Toma and H. Nakazawa and Y. Hirao and H. Uemura and S. Kagawa and H. Kanayama and Y. Nose and N. Kinukawa and Tsuyoshi Nakamura and N. Jinnai and Toyokazu Seki and Masanobu Takamatsu and Y. Masui and S. Naito and O. Ogawa},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={2007},
  volume={25 19},
  pages={
          2785-91
        }
}
  • N. Ito, M. Eto, +17 authors O. Ogawa
  • Published 2007
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE To clarify the effect of genetic polymorphisms on the response to interferon alfa (IFN-alpha) for metastatic renal cell carcinoma (MRCC), and to find a reliable molecular marker to select those patients with MRCC who would benefit from IFN-alpha immunotherapy. PATIENTS AND METHODS We carried out an association study in which 463 single nucleotide polymorphisms (SNPs) in 33 candidate genes were genotyped in 75 Japanese patients who had received IFN-alpha for MRCC. RESULTS After… Expand
STAT3 polymorphism can predict the response to interferon-α therapy in patients with metastatic renal cell carcinoma.
TLDR
This is the first prospective study demonstrating that a STAT3 polymorphism can be a predictive marker for treatment with IFN-α for patients with mRCC, and generated in Japanese patients and should be studied in other ethnic groups. Expand
STAT3 polymorphism rs4796793 may be a predictive factor of tumor response to multiple tyrosine kinase inhibitors in metastatic renal cell carcinoma in Japanese population
TLDR
The rs4796793 genotype is a novel predictive factor of the response to mTKIs in patients with mRCC, and prospective translational trials with larger patient cohorts are required to confirm these results. Expand
STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFNα Therapy in Stage III Melanoma Patients
TLDR
The analyses did not reveal a significant association between the STAT3 rs4796793 SNP and patients’ progression free or overall survival when IFNα treated and untreated patients were compared. Expand
Genetic polymorphisms of STAT3 correlated with prognosis in diffuse large B-cell lymphoma patients treated with rituximab
TLDR
It is suggested that STAT3 polymorphisms could be a suitable biomarker related to clinical outcome of DLBCL patients treated with rituximab and homozygous genotypes GG and CC showed advantages of long-term survival compared with heterozygousgenotype patients. Expand
A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon α
TLDR
Low levels of STAT3 mRNA correlated with rs6503691 genotype are concluded to be associated with the STAT3 expression levels and response of CML patients to IFN. Expand
YB-1 suppression induces STAT3 proteolysis and sensitizes renal cancer to interferon-α
TLDR
Y-box binding protein-1 (YB-1) was poorly expressed in T lymphocytes, as compared with cancer tissues, and suppression of STAT3 by Yb-1 inhibition did not seem to enhance the potential risk for autoimmune disorders. Expand
The effectiveness of interferon-alpha subtypes alternation for metastasis from renal cell carcinoma.
TLDR
Alternating IFN-α therapy for mRCC can be attempted even if other cytokines are not effective, and the response rate was 7% and disease control rate was 27%. Expand
Serum interferon alpha receptor 2 mRNA may predict efficacy of interferon alpha with/without low-dose sorafenib for metastatic clear cell renal cell carcinoma
TLDR
A high serum level of IFNAR2 mRNA may be a useful marker for predicting the response of metastatic RCC to IFN-alpha ± sorafenib therapy. Expand
Prognosis of metastatic renal cell carcinoma with first‐line interferon‐α therapy in the era of molecular‐targeted therapy
TLDR
The present study suggests that first‐line IFN‐α is still a useful therapy for mRCC even in the era of molecular targeted therapy. Expand
STAT3 rs3816769 polymorphism correlates with gene expression level and may predispose to nonsmall cell lung cancer: a preliminary study.
TLDR
It has been shown that rs3816769 STAT3 gene polymorphisms are associated with NSCLC susceptibility and might be regarded as having a significant functional and diagnostic value. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 25 REFERENCES
Genetic polymorphisms of the interleukin-4 receptor alpha gene are associated with an increasing risk and a poor prognosis of sporadic renal cell carcinoma in a Japanese population.
TLDR
The present findings show that the preferential Th2-type response to tumors was associated with a poorer prognosis and suggest that polymorphisms of the IL-4Ralpha gene may serve as useful genetic markers for assessing the risk of the development and progression of RCC. Expand
Prospective randomized trial of interferon alfa-2a plus vinblastine versus vinblastine alone in patients with advanced renal cell cancer.
TLDR
The combination of IFNalpha2a plus VLB is superior to VLB alone in the treatment of patients with locally advanced or metastatic renal cell carcinoma, and this is the first study to demonstrate that survival can be prolonged by using IFN alpha2a for these patients. Expand
Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells.
TLDR
It is indicated that constitutive SOCS3 expression affects the IFN-alpha sensitivity of CML cell lines and blast cells from patients with CML blast crisis. Expand
Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome.
TLDR
The results indicate a high frequency of STAT3 activation in renal cell carcinoma, especially in metastatic disease, and suggest that the activation ofSTAT3 contributes to the development and progression of renalcell carcinoma. Expand
Stat proteins and oncogenesis.
  • J. Bromberg
  • Biology, Medicine
  • The Journal of clinical investigation
  • 2002
TLDR
Evidence is considered of the evidence implicating Stat proteins, particularly Stats 1, 3, and 5, in tumor formation and progression and the role of this protein in a number of biological functions had to be determined in conditional knockouts. Expand
Renal cell carcinoma: review of novel single-agent therapeutics and combination regimens.
  • R. Amato
  • Medicine
  • Annals of oncology : official journal of the European Society for Medical Oncology
  • 2005
TLDR
Based on preliminary and limited studies, combination therapies offer the greatest clinical benefit in the management of this malignancy, although additional basic research is still warranted. Expand
Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNα
TLDR
Data show that SOCS-3 does not inhibit Stat3 activation, growth, and survival in CTCL, and SOCS3 is therefore not a tumour suppressor but rather a protector of tumour cells. Expand
STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma.
TLDR
Findings indicate that the aberrant expression of SOCS-3 is mediated by a constitutive activation of STAT3 in CTCL cells and affects the IFN-alpha sensitivity of these cells. Expand
STATs in oncogenesis
TLDR
The evidence for critical roles of STATs in oncogenesis is presented and the potential for development of novel cancer therapies based on mechanistic understanding of STAT signaling is discussed. Expand
Power of logrank test and Cox regression model in clinical trials with heterogeneous samples.
TLDR
A flexible and efficient method of estimating treatment effects adjusting for prognostic factors and the Cox regression method with a special hazard model is recommended to address the problems due to heterogeneity. Expand
...
1
2
3
...